Saturday 17 October 2026 Export CADL’s income statement to Excel — free account

Candel Therapeutics, Inc.

Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00. In the quarter to June 2026, EPS fell 477.8%, free cash flow fell 93.4% and total debt rose 525.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

8.19 0.72 −8.08%

Follow CADL

Alert me

Market cap: $681.8M
P/E: 0.0×
Fwd P/E: −1.8×
Dividend yield: —
F-score: 1/9
Altman Z: −1.20
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 3.00

Total sells 3.55

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	1	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	2	—	1	1	—

Insider Ownership 17.25%

Capital & Financial Ratios $m

Market Cap 681.78

Revenue 0.13

Net Income (88.53)

Free Cash Flow (57.29)

Net Debt (153.73)

Current Ratio 16.09

Debt/Equity 0.38

P/E ratio 0.00

Fwd P/E (1.76)

P/S ratio 4,857.08

P/B ratio 4.81

Past 5Y EPS Growth —

This Y EPS Growth (86.69%)

Next Y EPS Growth 20.52%

Next Y revenue growth (87.60%)

Next 5Y EPS Growth 34.45%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 94.06%

10-year low 10-year high

P/B against its own 10 years 82.28%

10-year low 10-year high

EV/Sales against its own 10 years 93.56%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	35	103	120	202
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	37	104	121	204

	2023	2024	2025	Q'26
Payables	0	0	1	5
ST’ Debt	9	10	—	—
Other	—	22	0	0
	14	38	9	13

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	0.00%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	2.86%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	0	0	0	0	0
’21	0	0	0	0	0
’20	0	0	0	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(18)	(17)	—	—	—
’25	(9)	(9)	(10)	(11)	(38)
’24	(8)	(6)	(7)	(6)	(27)
’23	(11)	(7)	(9)	(7)	(34)
’22	(8)	(7)	(9)	(7)	(31)
’21	(6)	(4)	(7)	(5)	(22)
’20	(2)	(4)	(2)	(3)	(9)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(17)	—	—	—
’25	(9)	(9)	(10)	(11)	(39)
’24	(8)	(6)	(7)	(6)	(27)
’23	(11)	(7)	(9)	(7)	(35)
’22	(8)	(8)	(10)	(7)	(33)
’21	(6)	(5)	(7)	(6)	(24)
’20	(2)	(4)	(2)	(4)	(11)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.14)	(0.52)	—	—	—
’25	0.13	(0.09)	(0.21)	(0.54)	(0.72)
’24	(0.28)	(0.74)	(0.33)	(0.40)	(1.74)
’23	(0.30)	(0.33)	(0.29)	(0.38)	(1.31)
’22	(0.03)	(0.14)	(0.30)	(0.18)	(0.65)
’21	(0.38)	(1.46)	(0.69)	0.05	(1.91)
’20	(0.06)	(0.25)	(0.22)	—	(1.52)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	5.51	1.40	0.66	1.16	4.25	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	14.78	8.10	3.06	14.60	13.68
People
People	Employees	—	—	—	—	50	65	76	42	38	55
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	0	0	0	0	—	—	—
	Gross margin, %	—	—	—	0.00	100.00	100.00	100.00	—	—	—
	EBT	—	—	—	(8)	(18)	(36)	(19)	(38)	(55)	(38)
	EBT margin, %	—	—	—	(6,592.00)	(14,144.00)	(28,899.20)	(15,035.20)	0.00	0.00	0.00
	Net income	—	0	—	(8)	(18)	(36)	(19)	(38)	(55)	(38)
	Depreciation	—	—	—	0	0	0	1	1	1	1
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.01	0.01	0.00	0.00	0.00	0.00
	Earnings	—	—	—	(0.28)	(1.52)	(1.91)	(0.65)	(1.31)	(1.74)	(0.72)
	Cash flow	—	—	—	(0.18)	(0.78)	(1.18)	(1.09)	(1.18)	(0.85)	(0.72)
	Capex	—	—	—	0.00	(0.13)	(0.10)	(0.04)	(0.01)	0.00	(0.01)
	Free cash flow	—	—	—	(0.18)	(0.91)	(1.27)	(1.13)	(1.19)	(0.85)	(0.73)
	Book value	—	—	—	1.41	(2.03)	3.40	1.66	0.44	2.09	0.98
	Shares, m	—	—	—	29	12	19	29	29	32	53
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	—	—	—
	P/S	—	—	—	661.64	661.64	1,180.70	408.14	—	—	—
	P/B	—	—	—	0.00	0.00	2.30	1.07	—	—	—
	EV/Sales	—	—	—	473.49	473.49	527.76	18.19	—	—	—
	EV/FCF	—	—	—	(3.43)	(3.43)	(2.74)	(0.07)	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(5)	(9)	(22)	(31)	(34)	(27)	(38)
	Capex	—	—	—	0	(1)	(2)	(1)	0	0	(1)
	Free cash flow	—	—	—	(5)	(11)	(24)	(33)	(35)	(27)	(39)
Balance, $m
Balance, $m	Working capital	—	—	—	44	30	80	66	23	66	112
	Total debt	—	—	—	0	1	1	21	21	12	47
	Net debt	—	—	—	(45)	(34)	(82)	(49)	(14)	(90)	(73)
	Shareholders’ equity	—	—	—	41	(24)	64	48	13	66	52
Returns, %
Returns, %	ROA	—	—	—	(35.90)	(42.00)	(56.67)	(22.52)	(63.82)	(74.53)	(32.91)
	ROIC	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	—	52.15	111.90	(178.06)	(33.61)	(125.50)	(139.56)	(64.58)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Dec 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OABI OmniAb, Inc.	$687.7M	— (loss-making)	— (loss-making)	+244.24% (above 0%: growing)	n/m	+211.16% (above 0%: growing)	95.45%	(49.47%)	Compare
ANNX Annexon, Inc.	$682.5M	— (loss-making)	—	—	n/m	−26.41% (below 0%: shrinking)	0.00%	0.00%	Compare
MDXG MiMedx Group, Inc	$682.2M	111×	— (loss-making)	−34.73% (below 0%: shrinking)	n/m	−174.83% (below 0%: shrinking)	68.96%	(28.69%)	Compare
CADL Candel Therapeutics, Inc.	$681.8M	— (loss-making)	— (loss-making)	0.00%	n/m	−93.35% (below 0%: shrinking)	0.00%	0.00%
PHAR Pharming Group N.V. Sponsored ADR	$681.6M	62.4×	— (loss-making)	−3.22% (below 0%: shrinking)	−57.14% (below 0%: shrinking)	−183.87% (below 0%: shrinking)	83.92%	1.44%	Compare
GYRE Gyre Therapeutics, Inc.	$678.6M	— (loss-making)	— (loss-making)	−2.12% (below 0%: shrinking)	n/m	−130.45% (below 0%: shrinking)	92.41%	(49.35%)	Compare
AURA Aura Biosciences, Inc.	$657.5M	— (loss-making)	—	—	n/m	−56.26% (below 0%: shrinking)	0.00%	0.00%	Compare
DSGN Design Therapeutics, Inc.	$655.9M	— (loss-making)	— (loss-making)	—	n/m	−7.00% (below 0%: shrinking)	0.00%	0.00%	Compare
PRME Prime Medicine, Inc.	$654.8M	— (loss-making)	— (loss-making)	+3.50% (above 0%: growing)	n/m	+4.40% (above 0%: growing)	100.00%	(3,750.87%)	Compare
Median of peers	$680.1M	—	—	−2.12%	—	−41.33%	76.44%	(14.34%)

All 614 Biotechnology stocks →

Candel Therapeutics, Inc. (CADL) key facts

Concern: Candel Therapeutics, Inc. reported a net loss of $38.2 million, or a loss of $0.72 per share, for fiscal 2025.
Candel Therapeutics, Inc. (CADL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Candel Therapeutics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $125,000.00.
As of October 16, 2026, CADL traded at $8.19, a market capitalization of $681.8 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4,857× sales.
Return on equity was −64.6% and debt-to-equity 0.38.
Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −1.20 (distress zone) for fiscal 2022.